ArticleThe Journal of antibiotics2026
Endophytic extract from Zanthoxylum piperitum as a promising source of anti-SARS-CoV-2 agents.
Article in The Journal of antibiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Endophytic fungi produce secondary metabolites that protect their host plants from external threats, and this symbiotic system represents a promising source of antiviral compounds. In this study, we evaluated the anti- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) activity of culture extracts from endophytic fungi isolated from Zanthoxylum piperitum. Among the 12 isolates tested, six exhibited significant antiviral activity in SARS-CoV-2-infected cells, and three of these showed distinct inhibitory effects on the viral 3C-like (3CL) protease. Chemical analysis of the active extracts identified sapinopyridione-produced by a Botryosphaeria endophyte-as the principal active metabolite. This compound displayed potent anti-SARS-CoV-2 activity, with a half-maximal inhibitory concentration (IC
Identifiers
42919855What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.